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Abstract. Norfloxacin. an oral fluoroquinolone (dose 400 mg daily). was compared to a placebo in a double blinded randomized tral for the prophylaxis of travelers' diarrhea. The study was of U.S. Navy and Marine Corps personnel on shore leave in Alexandria, Egypt. A total of 222 subjects were available (105 norfloxacin. 117 placebo). In the placebo group, 26% (30/117) developed acute diarrhea vs. 2% (2/105) in the norfloxacin group. There were no significant side effects in either group.
Acute diarrhea is a concern for travelers tandrna. Egypt. alter completing a I week port call developing countries. Although a diarrheal ill-to Naples. Italy. volunteers were recruited from ness rarely produces mortality in healthy popu-the crew of >5,000. Since departing the United lations. it can ir.,pair an individual's ability to States, the earner had visited no other ports befunction. Attack ;-ates vary, but reports of up to fore traveling to Naples and Alexandria. 40% are not unct-mmon.' Numerous strategies A brief history was taken from potential stud,. involving dietary discretion, bismuth subsali-subjects to determine eligibility. Volunteers were cylate prophylaxis and 'ntihiotic prophylaxis disqualified if they gave a history of sensitivit" have been tried to prevent acute diarrhea.' -' to quinolone antibiotics. renal disease ofany type. Norfloxacin, the first fluoroquinolone to be ap-or diarrhea in the prior month. Informed consent proved in the United States, has excellent in vitro was obtained from each volunteer, and a preactivity against most known bacterial enteric treatment stool specimen was collected. Subjects pathogens. including Campylobacter. Vibros, and were blindly randomized to receivt either norYersmnha.6 It is well tolerated, and resistance apfloxacin (400 mg once a day) or an identical apparently does not develop as rapidly as with nalpearing placebo. idixic acid.' Bacterial enteropathogens resistant Study subjects were instructed to take I capto other antibiotics are common in Egypt, and sule daily beginning the day prior to arrival in may decrease the effectiveness of prophylactic Alexandria and to continue until the morning of antibiotics.' I The drug was found to be effective the ship's departure (7 days). Participants were at a dose of 200 mg twice daily in Swedish tourinstructed to report to the medical department ists traveling in Africa, Asia. and Latin Ameriimmediately if diarrhea developed. ca.'" Among students traveling to Mexico, it was Diarrhea was defined as 4 unformed stools in 88% effective, and resistant bacteria were not a 24 hr period, or 3 unformed stools plus any of observed." the following: abdominal pain, cramps. fever, Although the general use of prophylactic annausea, or vomiting. Diarrhea developing after tibiotics by travelers has been discouraged, it may arrival in port and within 96 hr of leaving Albe appropriate in selected populations. This study exandria was attributed to the port call. Ifa subwas undertaken to evaluate the efficacy of nor-ject developed diarrhea. study prophylaxis was floxacin in preventing travelers' diarrhea among discontinued and the subject was treated as clin-U.S. Navy and Marine Corps personnel visiting ically indicated. Alexandria. Egypt.
Each subject was asked to complete a questionnaire designed to assess compliance, poten-
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tial side effects, locations visited, and dietary habits while ashore. Questionnaires were comThe study was conducted during August and pleted either when the subject developed diarSeptemiier 1988 on board the USS John F. Ken Of these. 20 did not return for medication. Wkhen present on the initial culture. 5 colonies 15 withdrew prior to reachingA lexandria or took of 1. ,, h wefQ selected and 11-roien at -20*C.
no Pills. 2 transferred fmhm the ship. 2 did not Each was assayed fbr heat labile (LT) and heat respond to attempts at follow-up. and I went on -,tahle iST) enterotoxin using commercially emergency leave. making a total of'4( volunteers .ivalable )N A probes (DuPont. Wilmington. who did not complete the studsN. -\ total of 222 D) Enteroadhereni F ,oh strains (EAEC) Were remained for analysis. identified hy adherence to HEp-2 cells in the Prec-treatment stools \%ere submitted by 129 of' presenCe of D-mannosc.
Slide agglutination the subtects completing the studs,. The number i llio.\lerieux. Francei was used to identify enof these pre-treatment stools posiise for enteric ieropaihogenick -w strains (EPEC) and all colpathogens ini the placebo anci nortloxacin groups onics that were sorhitol negative on Sorbitolwere not statistically diffierent (3 61)) s~. 460. reMlac( onke% agar were serot,,ped with 0: 1 5 antispectivels . Pre-Alexandria positive cultures Inserumn to screen I .or enterohemcrrhagic L' c/i eluded 5 enterotox;genic !-. o/h (ETEC) 13-LI +. (lIL( 'I !)IF(O0 Labs. Detroit. MI). All L' co/h 2-1. -ST -( and 2 EAEC. None oithe subjects that were initial Ismin decarbosslase negative with positise pre-treatmient stools developed aind n,,nmotilr: were further in'estigated for endiarrhea. teroinsasiseness b% the Set-ens iest."~ As noted in Tables I anti 2 . there were no Vhec presence ot proto/oa and helminthie pardifferences between the placebo and nortioxacin aitos was assessed h\ direct microscopic exgroups in terms of age. days ashore, number of' .irnaiion of fresh stool and specimens prepared mecals, or ispes of' foods eaten. \lost subjects hs ritolaie-io~dine-lor-nialin cone-~ration enrolled in the stud% made an organized excur-(Ill( ) Methanoilixed smears were stained with sbon to (. airo as well as slas trips to Alexandria. a n;diticdCL .icd fast stain and cxamincd for Crip.
rhe freiquencN of compliance and side effects i, ';,',r1ihu,,i oic\ 0t% Stools "ere also examined did noi difli'r between the groups. Subject% in the or :,ait if us l-\ an ten/s me-linked immunosornorfloxacin and placebo groups reported missing hernt iasa lRotais me. Abboit Laboratories), a mean oit 0) 5 I I andi 0.2 -i 0 doses. re-1,taiistical anal' sis wats performed using SPSS specis el% iP -' ) i) ' Side eilects were reported I'C 1jtatitical package 1SPSS Inc.. C~hicago, 11.).
in 2 '%-t ot th, placebo group and 4'o of the nori, f hi -s(uare test wAith N ate% correction w-as tioxacin gioup il L4t 1-hic e scrc 2 repots T
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of headache and I report each of dizziness. uri- 
